medigraphic.com
ISSN 0185-6014 (Impreso)
Órgano oficial de difusión de la Federación Mexicana de Patología Clínica, AC y de la Asociación Latinoamericana de Patología Clínica/Medicina de Laboratorio

2015, Número 2

<< Anterior Siguiente >>

Rev Mex Patol Clin Med Lab 2015; 62 (2)


Staphylococcus aureus asociado a la comunidad (CA-MRSA)

Cervantes GE, García GR, Salazar SPM

Idioma: Español
Referencias bibliográficas: 52
Paginas: 100-111
Archivo PDF: 385.67 Kb.


RESUMEN

La rápida diseminación de las infecciones por Staphylococcus aureus meticilina resistente adquirido en la comunidad (CA-MRSA) surgió en las décadas pasadas. Se presenta en gente joven en ausencia de factores de riesgo y sin haber asistido a algún centro de salud o haber sido hospitalizado. Las tasas de prevalencia reportadas de los CA-MRSA varían ampliamente en los estudios realizados debido a las diferentes definiciones empleadas y diversos establecimientos de los CA-MRSA en donde éstos se han realizado. La mayoría de las infecciones causadas por los CA-MRSA son en piel y tejidos blandos, pudiendo conducir, dependiendo de la severidad de las mismas, a la muerte del paciente. Asimismo, tales infecciones se han asociado a cepas de estafilococos que comparten el cassette cromosomal estafilocócico mec (SCCmec) tipo IV y a los genes que codifican la leucocidina Panton Valentine (PVL). Actualmente, la emergencia de los MRSA prevalece en la comunidad como un problema de salud pública grave. Por lo que se necesitan tanto programas de vigilancia y diagnóstico como un manejo especial para las infecciones confirmadas por MRSA.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Pahissa A. Infecciones producidas por Staphylococcus aureus. Barcelona, España: ICG, Marge, SL; 2009.

  2. Moreillon P, Que Y, Glauser M. Staphylococcus aureus. In: Mandell GL, Bennett JE, Olin R. Principles and practice of infectious diseases. 6a ed. Philadelphia: Churchil Livington; 2005.

  3. Crossley KB, Jefferson KK, Archer GL, Fouler VG Jr. Staphylococci in human disease. 2nd edition. Oxford: Wiley-Blackwell; 2009.

  4. Cervantes-García E, García-González R, Salazar-Schettino PM. Características generales de Staphylococcus aureus. Rev Latinamer Patol Clin. 2014; 61: 28-40.

  5. Cervantes-García E, García-González R, Salazar-Schettino PM. Importancia de Staphylococcus aureus meticilina-resistente intrahospitalario y adquirido en la comunidad. Rev Latinamer Patol Clin. 2014; 61: 196-204.

  6. Daum R. Skin and soft tissue infections caused by methicillin-resistant Staphylococcus aureus. J Am Med Association. 2007; 35: 380-390.

  7. Davis S, Perris M, Donabedian S, Manierski C, Singh A, Vager D. Epidemiology and outcomes of community-acquired methicillin-resistant Staphylococcus aureus infection. J Clin Microbiol. 2007; 45: 1705-1711.

  8. Klevens M, Morrison M, Nadle J, Petit S, Gershman K, Ray S. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. J Am Med Association. 2007; 298: 1763-1771.

  9. Kuehnert M, Kruszon-Moran D, Hill H, McQuillan G, McAllister S, Fosheim G. Prevalence of Staphylococcus aureus nasal colonization in the United States, 2001-2002. J Infect Dis. 2006; 193: 171-179.

  10. Hiramatsu K, Cuil L, Kuroda M, Ito T. The emergente and evolution of methicillin-resistant Staphylococcus aureus. Trends Microbiol. 2001; 9: 486-493.

  11. Moran GJ, Krishnadasan A, Gorwit RJ, Fosheim GE, McDougal LK, Carey RB et al. Methicillin-resistant Staphylococcus aureus infections among patients in the emergency department. N Engl J Med. 2006; 355: 666-674.

  12. Reyes J, Rincón S, Díaz L. Dissemination of methicillin-resistant Staphylococcus aureus USA300 sequence type 8 linage in Latin America. Clin Infect Dis. 2009; 49: 1861-1867.

  13. Ma XX, Galiana A, Pedreira W. Community-aquired methicillin-resistant Staphylococcus aureus, Uruguay. Emerg Infect Dis. 2005; 11: 973-976.

  14. Moellering RC Jr. The growing menace of community-acquired methicillin-resistant Staphylococcus aureus. Ann Intern Med. 2006; 144: 368-370.

  15. Growitz RJ. A review of community-associated methicillin-resistant Staphylococcus aureus skin and sofa tissue infections. Pediatr Infect Dis J. 2008; 27: 1-7.

  16. Crawford SE, Boyle-Vavra S, Daum RS. Community-associated methicillin-resistant Staphylococcus aureus. In: Scheld WM, Hooper DC, Huges JM editors. Emerging infections. Washington, DC: ASM Press; 2007.

  17. van Duijkeren E, Wolfhagen MJ, Heck ME, Wannet WJ. Transmission of Panton valentine leukocidin-positive, methicillin-resistant Staphylococcus aureus strain between humans and a dog. J Clin Microbiol. 2005; 43: 6209-6211.

  18. Diep BA, Otto M. The role of virulence determinants in community associated MRSA pathogenesis. Trends Microbiol. 2008; 16: 361-368.

  19. Hanssen AM, Ericson-Sollid JU. SCCmec in staphylococci: genes on the move. FEMS Immunol Med Microbiol. 2006; 46 (1): 8-20.

  20. Ito T, Ma XX, Tekeuchi F, Okuna K, Yuzawa H, Hiramatsu K. Novel type V staphylococcal cassette chromosome mec driven by a novel cassette chromosome recombinase, ccrC. Antimicrob Chemoter. 2004; 48: 2637-2651.

  21. Chambers HF, DeLeo FR. Waves of resistance: Staphylococcus aureus in the antibiotic era. Nature Rev Microbiol. 2009; 7: 629-641.

  22. Uhlemann AC, Otto M, Lowy FD, DeLeo FR. Evolution of community and healthcare-associates methicillin-resistant Staphylococcus aureus. Infec Gen Evolution. 2013; 21: 563-574.

  23. Nami TS, Le Dell KH, Sabatti K, Borchadt SM, Boxrud DJ, Elianne J. Comparison of community and health care associated methicillin-resistant Staphylococcus aureus infection. JAMA. 2003; 290: 2976-2984.

  24. Khanna T, Friendship R, Dewey C, Weese JS. Methicillin-resistant Staphylococcus aureus colonization in pigs and pig farmers. Vet Microbiol. 2008; 128: 298-303.

  25. Anderson ME, Lefabre SL, Weese JS. Evaluation of prevalence and risk factors for methicillin-resistant Staphylococcus aureus colonization in veterinary personnel attending and international equine veterinari conference. Vet Micribiol. 2008; 129: 410-417.

  26. Tenover F. Community –associated methicillin– resistant Staphylococcus aureus: it’s not just in communities anymore. Clin Microbiol Newsletter. 2006; 28: 33-36.

  27. Faria NA, Oliveira DC, Westh H, Monnet DL, Larsen AR, Skov R. Epidemiology of emerging methicillin resistant Staphylococcus aureus (MRSA) in Denmark: a nationwide study in a country with low prevalence of MRSA infection. J Clin Microbiol. 2005; 43: 1836-1842.

  28. Kennedy AD, Otto M, Braughton KR, Whitney AR et al. Epidemic community associated methicillin-resistant Staphylococcus aureus resent clonal expansion and diversification. Proc Nat Acad Sci USA. 2008; 105: 1327-1232.

  29. Fridkin SK, Hageman JC, Morrison M, Sanza LT, Como-Sabetti K. Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med. 2005; 353: 1436-1444.

  30. Udo EE, Rearman JW, Grubb WB. Genetic analysis of community isolates of methicillin-resistant Staphylococcus aureus in Western Australia. J Hosp. 1993; 25: 97-108.

  31. Herold B, Immergluck L, Laurdeldale K, Gaselin R, Boyle-Vavra S. Community-acquired methicillin-resistant Staphylococcus aureus in children with indentified predisposing risk. J Am Med Assoc. 2007; 279: 593-598.

  32. von Eiff C, Becker K, Machaka K, Stammer H, Peters G. Nasal carriage as a source of Staphylococcus aureus bacteremia. Study group. N Engl J Med. 2001; 344: 11-16.

  33. Salgado CD, Farr BM, Calfee DP. Community-acquired methicillin-resistant Staphylococcus aureus: a meta-analysis of prevalence and risk factors. Clin Infect Dis. 2003; 36: 131-139.

  34. Europan Antimicrobial Resistance Survillance System (EARS). Summary of latest data on antibiotic resistance in the EuropeanUnion 2010. Available in: http://www.ecdc.europa.eu

  35. Diekema DJ, Pfaller MA, Schmitz FJ, Smayevsky J, Bell J, Jones RN et al. Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the western Pacific region for the SENTRY antimicrobial surveillance program, 1997–1999. Clin Infect Dis. 2001; 32 (Suppl 2): S114-32.

  36. Kennedy AD, De Leo FR. Epidemiology and virulence of community-Associated MRSA. Clin Microbiol Newsletter. 2009; 31: 153-159.

  37. De Leo FR, Diep BA, Otto M. Host defense and pathogenesis in Staphylococcus aureus infections. Infect Dis Clin North Am. 2009; 23: 17-34.

  38. Foster TJ. Immune evasion by staphylococci. Nat Rev Microbiol. 2005; 3: 948-958.

  39. Voyich JM, Braughton KR, Sturdevant DE, Whitney AR. Inshights mechanisms used by Staphylococcus aureus to avoid destruction by human neutrophils. J Immunol. 2005; 175: 3907-3919.

  40. Li M, Diep BA, Villaruz AE, Braughton KR, Jiang X, Deleo FR et al. Evolution of virulence in epidemic community-associated methicillin-resistant Staphylococcus aureus. Proc Natl Acad Sci USA. 2009; 106: 5883-5888.

  41. Vandenesch F, Naimi T, Enright MC, Lina G, Nimmo GR, Hefferan H et al. Community-acquired methicillin-resistant Staphylococcus aureus carring Panton-Valentine leukocidin genes: worldwide emergence. Emerg Infect Dis. 2003; 9: 978-984.

  42. King MD, Humprey BJ, Wang YF, Kourbatova EV. Emergence of community-acquired methicillin-resistant Staphylococcus aureus USA 300 clone as the predominant cause of skin and soft tissue infections. Ann Intern Med. 2006; 144: 309-317.

  43. Takano T, Higuchi W, Otsuka T, Baranovich T, Enany S, Saito K. Novel characteristics of community-acquired methicillin-resistant Staphylococcus aureus strains belonging to multilocus sequence type 59 in Taiwan. Antimicrob Agen Chemoth. 2008; 52: 837-845.

  44. Boyle-Vavra S, Daum RS. Community-acquired methicillin-resistant Staphylococcus aureus: the role of Panton-Valentine leukocidin. Lab Invest. 2007; 87: 3-9.

  45. Tenover FC, Goering RV. Methicillin-resistant Staphylococcus aureus strain USA 300: origin and epidemiology. J Antimicrobial Chemoter. 2009; 64: 441-446.

  46. Tewhey R, Cannavino CR, Leake JA, Bansal V, Topol EK. Genetic structure of community acquired methicillin-resistant Staphylococcus aureus USA300. BMC Genomics. 2012; 13: 508-514.

  47. Okuma K, Iwakawa K, Tumidge JD. Dissemination of new methicillin-resistant Staphylococcus aureus clones in community. J Clin Microbiol. 2002; 40: 4289-4294.

  48. Deureumberg RH, Vink C, Kalenic S, Friedrich AW, Bruggeman CA, Stobberingh EE. The molecular evolution of methicillin resistant Staphylococcus aureus. Clin Microbiol Infect. 2007; 13: 222-235.

  49. Monecke S, Slickers P, Elligton MJ, Kearns AM, Ehrich R. High diversity of Panton-Valentine leukocidin-positive, methicillin susceptible isolates of Staphylococcus aureus implications for the evolution of community-associated methicillin resistant S. aureus. Clin Microbiol Infect. 2007; 13: 1157-1164.

  50. Diep BA, Gill SR, Chang RF, Phan TH, Chen JH. Complete genome sequence of USA300, an epidemic clone of community-acquired methicillin-resistant Staphylococcus aureus. Lancet. 2006; 367: 731-739.

  51. Baba T, Takeuchi F, Kurdoa M. Genome and virulence determinants of high virulence community-acquired MRSA. Lancet. 2002; 359: 1819-1827.

  52. Enright MC, Robinson DA, Randle G, Feil EJ, Grundmann H, Spratt BG. The evolutionary history of methicillin-resistant Staphylococcus aureus (MRSA). Proc Natl Acad Sci USA. 2002; 99: 7687-7692.




2020     |     www.medigraphic.com